Clinical Trials
The Kentucky Clinical Trials Network
The Kentucky Clinical Trials Network (KCTN) is a centerpiece in the enabling legislation that states the Governance Board will “establish a statewide clinical trial network to make university-based clinical trials available to the community physician in order to bring the most innovative cancer treatments to all Kentuckians in need of these treatments.”
Leadership for the KCTN’s activities initiates with the Governance Board Chairman, the Network Medical Director, Network Director, and a practitioner-based Network Committee.
The KCTN vision, developed by the healthcare community, continues to drive network strategies to assure an alliance of regional, local, and university hospitals and community physicians united in the delivery of clinical trials throughout the Commonwealth. The network is an autonomous organization guided by the interests of multidisciplinary healthcare professionals; including medical oncologists, radiologists, and surgeons involved in developing/conducting innovative treatments for lung cancer patients.
As a continually developing program, the Network leadership team, Dr. Timothy W. Mullett, Medical Director, and Kris Damron, Network Director, are building a true collaboration across disciplines to use clinical and scientific expertise and existing resources to design and execute innovative and effective projects.
Click here to go to the Kentucky Clinical Trials Network website.
Research at Home:
Network members are conveniently located in every federal congressional district in the state, which allows patients to consider research opportunities while remaining at home. Patients remain under the direct care of trusted local physicians. Commuting to other geographical areas to participate in research is no longer a burden on patients and their families.
Network member physicians work with the Coordinating Center to select and build a research portfolio appropriate for their patient populations.
KENTUCKY CLINICAL TRIALS NETWORK
CURRENT STUDIES
Protocol No. |
Title |
Status |
|---|---|---|
AMGEN-20070782 |
Study to evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa administered at 500 ug once-every-three-weeks in Anemic subjects with Advanced Stage Non-small cell lung cancer receiving multi-cycle chemotherapy | Open |
| CTN-0501 | Randomized Phase II Trial of Carboplatin and Gemcitabine with or without Dexamethasone in Patients with Untreated Stage IIIB-pleural effusion and Stage IV Non-Small Cell Lung Cancer | Closed to Accrual |
| CTN-0601 | Lung Cancer Survival in Kentucky: A Multifactorial Approach | Open |
| GSK-MAGRIT | Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer | Closed to Accrual |
| H3E-US-S130 | Phase III Pemetrexed plus Carboplatin followed by Pemetrexed vs. Paciltaxel plus Carboplatin plus Bevacizumab followed by Bevacizumab in Advanced Non-small Cell Lung Cancer with Non-Squamous Histology" | Closed to Accrual |
| IMCLONE-CP11-0806 | Phase III study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients with Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) | Open |
| LUCANIX-BB-IND-8868 | Phase III Study of Lucanix(TM) as Maintenance Therapy for Patients with Stages III/IV NSCLC Who Have Responded to or Have Stable Disease Following One Regimen of Front-line Platinum-based Combination Chemotherapy | Open |
For additional information on study eligibility and to search for studies by treatment, disease type, and participating locations please click here: http://www.kctn.org/CurrentStudies/
To contact the KCTN Coordinating Center Team directly for study opportunities please click here: Kyclinicaltrialsnetwork@uky.edu
The University of Kentucky’s Markey Cancer Center houses the Network’s Coordinating Center, a hub for centralized operations. The Coordinating Center serves as liaison between industry sponsors and network investigators to ensure study initiation, conduct and close out are delivered efficiently and effectively.
Physician Opportunity:
A licensed physician practicing in the state of Kentucky interested in conducting research in compliance with applicable CFR regulations, ICH and KCTN guidelines may be eligible for Network Membership. Prospective members must fulfill KCTN membership requirements, including regulatory and site assessment, completion of Human Subjects Protection training, and submission of qualifying documents. A formal relationship is established and maintained with all Network members.
We assist physicians seeking to initiate or expand their research portfolio. Physicians are provided with resources needed to conduct research including; assessment and program development, mentoring, and research education. Network members are encouraged to initiate study concepts.
Industry Opportunity:
The Network is a resource for sponsors seeking multi-site study conduct. Site patient populations have some of the highest cancer incident rates in the country. Placing industry studies in the Network provides access to these unique patient populations utilizing a convenient one-stop shop in identifying potential sites, and centralized project activities including central pharmacy.
Our members are dedicated clinicians qualified by relevant expertise and training. Network sites are located throughout the state and include the University of Kentucky, the University of Louisville, private practice offices, hospitals, and health care systems.
Please contact us for additional information regarding membership and study placement: Kyclinicaltrialsnetwork@uky.edu
Learn More About Clinical Research:
University of Kentucky - Clinical Research Office
University of Louisville - Office of Research
Centerwatch